KR20160135569A - Whitening cosmetic composition comprising chromone derivatives - Google Patents

Abstract

The present invention relates to a whitening cosmetic composition containing a chromone derivative having a structure similar to that of aloesin derived from a natural product. The chromone derivative compound of the present invention is excellent in inhibiting the activity of a tyrosinase enzyme , It is possible to mass-synthesize, and it exhibits remarkably excellent whitening effect even when applied in a small amount, maximizes the whitening effect of the skin whitening ingredient, and has the advantage of using fewer side effects when using a derivative derived from a natural product.

Description

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a whitening cosmetic composition containing a chromone derivative,

The present invention relates to a whitening cosmetic composition containing a chromone derivative having a structure similar to aloesin derived from a natural product.

The most important determinant of human skin color is the distribution of melanin in the skin and the amount of melanin. Several factors affect melanin production in the skin. The development of a composition for suppressing the increase of melanin production caused by ultraviolet rays and the coloring of the pigment is important in the field of cosmetics.

First, the basic mechanisms of pharmaceuticals incorporated into whitening cosmetics for the prevention of pigmentation are: 1) inhibition of tyrosinase action, 2) inhibition of tyrosinase production, 3) inhibition of melanin production regulator, reduction of existing melanin, Suppression of photooxidation, promotion of melanin excretion, and finally, ultraviolet light.

Among these, tyrosinase enzyme is known to play the most important role in the melanin formation process. In this process, the enzyme acts on the tyrosine present in the tissue to produce dopaquinone, which in turn undergoes several stages of autoxidation from the dopaquinone to produce melanin. Therefore, attention has been paid to the fact that inhibition of the activity of tyrosinase enzyme can inhibit melanin production. Thus, in the conventional cosmetics field, aloesin, hydroquinone, tretinoin, kojic acid, arbutin, ascorbic acid, glutathione, Some methods have been used as active inhibitors.

More specifically, the human epidermis is affected by ultraviolet light and is stimulated. As a result, there are several enzymes involved in the synthesis of melanin in the melanosome, tyrosinase. Tyrosinase is an enzyme involved in the crucial initial rate determining step in the melanin biosynthetic pathway and tyrosinase induces the oxidation of tyrosine, a protein in the melanocyte. As a result of this mechanism, melanin is synthesized by oxidized tyrosine in the melanocyte of the basal layer of the skin at the bottom of the skin. Tyrosine is oxidized to the next DOFA quinone by DOFA.

The pigment produced in the human epidermis is divided into two major parts, eumelanogenesis, which produces brown and black pigment, and DHICA reaction from TRP-1 and DOFA chrome, a melanin intermediate. Two enzymes are involved in catalyzing TRP-2. Pheomelanogenesis, which produces yellow and red pigments, is divided into two mechanisms, which are the sulfur-containing amino acid cysteine and glutathione-related sulfur-containing reactions.

The skin should continue to have a whitening effect because it will continue to form melanin due to UV radiation from the sun. In addition, there are hormones that prevent whitening from continuing. There is no way to completely inhibit the activity of tyrosinase due to the actions of the sex hormones estrogen, progesterone and the like. Therefore, skin whitening efficacy can be expected by continuously using whitening functional cosmetics with little irritation. Another problem is that it is difficult to remove only melanin, which is a high molecular substance. Therefore, a chromone derivative of natural origin is used as a method of inhibiting tyrosinase, an enzyme involved in the initial rate determining step. Continuously use whitening functional cosmetics to maintain whitening.

Japanese Patent Laid-Open Nos. 94-56642, 94-56643 and 94-56644 disclose a method for increasing the whitening effect by adding one or more kinds of specific betaine derivatives (8-24 carbon atoms) There have been described examples in which one type of high alkyl sulfate ester or acyl methyl taurine is contained to promote the transdermal absorption of arbutin. These drugs can stimulate transdermal absorption to a certain extent, but have a problem of irritating the skin.

In addition, according to the prior art to date, it has been reported that a substance inhibiting tyrosinase is contained in the aloe extract (Akira Yagi Toshimitsu kanbera, and Naoko Morinobu. Planta Medica 1987; 53 (6), 515-517 ), The active substance is known to be a chromene derivative, aloe sine. For example, Korean Patent Laid-Open Publication No. 2008-0079126 discloses a whitening cosmetic composition containing aloe vera, licorice extract, rapeseed flower extract, and golden extract as effective ingredients. Compared to the case where each ingredient is used alone, It exhibits excellent inhibitory activity against the enzyme and exhibits excellent whitening effect.

However, since Aloecein has a C-C bond in the molecule within the molecular structure, it is difficult to synthesize it, which is costly to obtain a large amount of pure substance.

It has been disadvantageous in that a whitening effect as much as desired can not be obtained when a small amount of an effective ingredient is used in a whitening cosmetic product. Therefore, it is necessary to develop a whitening agent which has an excellent whitening effect while using a small amount of the existing whitening agent and has no side effects such as irritation to the skin. In addition, it is necessary to develop a whitening agent having industrial properties by developing new materials capable of mass production.

Japanese Patent Application Laid-Open No. 1994-56642 Japanese Patent Application Laid-Open No. 1994-56643 Japanese Patent Application Laid-Open No. 1994-56644 Korea Patent No. 451813 Korean Patent Publication No. 2008-0079126 Korean Patent No. 889604

Akira Yagi Toshimitsu kanbera, and Naoko Morinobu. Planta Medica 1987; 53 (6), 515-517

The present invention aims to provide a whitening ingredient which can overcome the disadvantages of the conventional whitening ingredients while developing a new whitening ingredient different from the conventional whitening whitening cosmetics. As a result of the research, The present inventors have completed the present invention by confirming that the enzyme can inhibit the activity of tyrosinase and can be mass-synthesized.

That is, an object of the present invention is to provide a cosmetic composition capable of maximizing the whitening effect of a skin whitening component, and it is an object of the present invention to provide a cosmetic composition which can exert an excellent whitening effect even when a small amount of the chromone derivative compound according to the present invention is used, The whitening effect of the component is maximized while the mass production is possible and the use of the derivative derived from the natural product has little side effects.

The present invention solves the above problems by providing a chromone derivative compound that exhibits an activity of inhibiting the activity of a tyrosyanase enzyme.

The present invention also solves the above problems by providing a method for mass-synthesizing the above-mentioned chromone derivative compounds.

The chromone derivative compounds according to the present invention are excellent in inhibiting the activity of tyrosinase enzyme, can be mass-synthesized, exhibit remarkably excellent whitening effect even when a small amount is applied, and maximize the whitening effect of skin whitening ingredients And the use of derivatives derived from natural products has the advantage of fewer side effects.

Fig. 1 shows a process for synthesizing a novel chromone derivative.
2 is a graph showing the tyrosinase residual activity (%) of a chromone derivative compound having a structure similar to aloesin.
FIG. 3 shows the expression of genes of tyrosinase, DOPA stain, TRP-1, TRP-2 and actin in B16-F10 melanoma cells of a chromogenic derivative compound having a structure similar to aloesin ≪ / RTI >

The present invention relates to a whitening cosmetic composition comprising a compound of the formula (1)

[Chemical Formula 1]

(2)

Wherein each of R ₁ and R ₂ is independently a hydrogen atom, a halogen atom, an alkoxy group, an OH group, an alkyl group, a cycloalkyl, an aryl or a monovalent group.

In one aspect of the invention, R ₁ is a hydrogen atom, a halogen atom, a C _{1 -} is selected from the group consisting of _4-alkoxy group, OH group, C _1-6 alkyl, cycloalkyl, aryl, and be put group,

In one aspect of the invention, R ₂ is a hydrogen atom, a halogen atom, C _{1 - 4} alkoxy are selected from the group, OH group, C _1-6 alkyl, cycloalkyl, aryl and the group consisting of ventilation be put.

In one embodiment of the present invention, the chromone derivative is characterized by inhibiting the activity of tyrosinase.

In one embodiment of the present invention, the content of the novel chromone derivative whitening compound having a structure similar to aloesin in the cosmetic composition is 0.000001 to 5.0% by weight, more specifically 0.001 to 1.0% by weight, have.

In one aspect of the present invention, the composition may be used as a skin lotion, a nutritional cream, a nutritional lotion, an eye cream, an essence, a cleansing cream, a cleansing lotion, a pack, a body lotion, a body cream, a body essence, a makeup base, And patches. [0040] The term " a "

In one aspect of the present invention, the present invention relates to a novel chromone derivative whitening compound having a structure similar to aloesin, which comprises a pharmaceutically acceptable salt thereof as an active ingredient and provides a skin external preparation for preventing or alleviating spots and freckles do.

In one embodiment of the present invention, the external preparation for skin may be formulated into any one selected from the group consisting of ointments, creams, lotions, liquids, dressings, patches, foams, tapes, aerosols, external powders and spraying agents .

In one embodiment of the present invention, the chromone derivative compound having the whitening activity can be used in combination with other whitening ingredients.

Hereinafter, the present invention will be described in more detail.

In the present invention, Aloesin is a component isolated from Aloe which has been used for a long time as a medicinal plant. Aloe has been used for burns and other skin diseases in indigenous medicine from ancient times, and actually contains many physiologically active substances in aloe, which helps to treat diseases of digestive system as well as trauma. In recent years, its use has been expanding to health foods and cosmetics, and research on beauty has also been actively conducted. Aloe is Aloe bardensis Mii There are more than 300 species of native plants, with about 130 species of Aloe spp. Distributed only in South Africa. It has been reported that aloesin inhibits the activity of tyrosinase existing in human melanocytes and basically blocks the process of converting tyrosine into melanin, thereby exhibiting a whitening effect. The aloesin used in the present invention may be prepared by methods known in the art, for example, see Akira Yagi, Kenji Makino and Itsuo Nishioka, Chem. Pharm. Bull. 25 (7), 1771-1776, 1977 / Kim, KK, Aloe vera in aloe preparations by high performance liquid chromatography, 1996). For example, the whole leaves of aloe vera are washed thoroughly and then extracted with a lower alcohol such as methanol, ethanol, propanol, butanol or the like, a lower ketone such as acetone, methyl ethyl ketone or a mixture thereof, and the extract is suspended in water A lower ester such as ethyl ether or the like, a lower ester such as ethyl acetate, a halogenated hydrocarbon solvent such as carbon tetrachloride, dichloromethane or chloroform, or a mixture thereof, extracting the aqueous layer with a lower alcohol again, The lower alcohol is mixed at a ratio of 2: 1 to 100: 1, preferably 5: 1 to 20: 1, or a mixed solvent or lower ester, lower alcohol and water at a ratio of 20: 1: 0 to 6: 4: ≪ / RTI > by subjecting the resulting mixture to silica gel column chromatography using a mixed solvent as an eluent .

The whitening cosmetic composition according to the present invention can be used for external medicine, cosmetics and the like. Formulations may include ointments, tinctures, soaps, and conventional cosmetics such as creams, cold creams, lotions, milk lotions, nutritional creams, essences, foundations, and perfumes. When they are formulated, they may be formulated into adjuvants and excipients conventionally used in the field of external medicine, soap base and cosmetics, such as emulsifiers, preservatives, lubricants, diluents, thickeners, moisturizers, pigments, -0079126 can be used according to a method conventionally used in the manufacture of cosmetics.

Examples of the moisturizing agent include one or two of moisturizing agents conventionally used such as ethylene glycol, diethylene glycol, triethylene glycol, polyethylene glycol, propylene glycol, dipropylene glycol, 1,3-butylene glycol, glycerin, sorbitol, collagen, More than two species can be used.

As the emulsifying agent, cyclomethicone, polymethyl methacrylate, or hydrogenated castor oil may be used.

Examples of the thickening agent include methylcellulose, carboxymethylcellulose, carboxymethylhydroxyguanine, hydroxymethylcellulose, hydroxyethylcellulose, carboxyvinyl polymer, polyquaternium, cetearyl alcohol, stearic acid, carrageenan and the like.

As the preservative, imidazolidinyl urea, methyl paraben, propyl paraben and the like can be used.

The whitening ingredients used in the compositions according to the present invention are all those whose stability has already been established and can be used without side effects. In the present invention, the amount of each component Can be remarkably reduced, so that the composition of the present invention containing them can also be used safely with little side effects.

The emulsifying agent is emulsified in a homogenizer during the production of a cosmetic preparation, and an appropriate amount of perfume is added thereto, followed by stirring and mixing to obtain the title product.

In one aspect of the present invention, the present invention relates to a novel chromone derivative whitening compound having a structure similar to aloesin, which comprises a pharmaceutically acceptable salt thereof as an active ingredient and provides a skin external preparation for preventing or alleviating spots and freckles do.

In one embodiment of the present invention, the external preparation for skin may be formulated into any one selected from the group consisting of ointments, creams, lotions, liquids, dressings, patches, foams, tapes, aerosols, external powders and spraying agents .

In the case of ointments, creams, gels and lotions, 0.01 to 10 w / v%, and 0.01 to 10 w / v%, respectively, of the chromone derivative whitening compound having a structure similar to aloesin varies depending on the preparation. 0.01 to 10 w / v% for a tape preparation, and 0.01 to 10 w / v% for an external preparation.

Other ingredients than the active ingredient of the formulation of the present invention may be any ingredient commonly used in external preparations. In the case of ointments, creams, gels and lotions, there may be used white petrolatum (vaseline), yellow petrolatum, lanolin, purified beeswax, cetanol, stearyl alcohol, stearic acid, hydrogenated oil, hydrocarbon gel, polyethylene glycol, liquid paraffin and squalane A mechanism such as; Oleic acid, isopropyl myristate, glycerol triisooctanoate, crotamitone, diethyl sebacate, diisopropyl sebacate, diisopropyl adipate, hexyllaurate, fatty acid, fatty acid ester, vegetable oil, Solvents or stabilizers such as alcohols; Tocopherol derivatives, antioxidants such as L-ascorbic acid, dibutylhydroxytoluene and butylhydroxyanisole; preservatives such as p-hydroxybenzoate; Curling agents such as glycerin, propylene glycol and sodium hyaluronate; Surfactants such as polyoxyethylene derivatives, glycerol fatty acid esters, sucrose fatty acid esters, sorbitan fatty acid esters, propylene glycol fatty acid esters and lecithin; Thickening agents such as carboxyvinyl polymer, xanthan gum, carboxymethylcellulose and sodium carboxymethylcellulose, hydroxypropylcellulose and hydroxypropylmethylcellulose; Stabilizers; Preservatives; Adsorption promoters; And other suitable fillers may be added.

In the case of the blowing agent, an adhesive such as a polyacrylic acid and a polyacrylic acid copolymer; A crosslinking agent such as aluminum sulfate, aluminum potassium sulfate, aluminum chloride, magnesium aluminometasilicate and dihydroxy aluminum aminoacetate; Thickening agents such as sodium polyacrylate, polyvinyl alcohol, polyvinylpyrrolidone, gelatin, sodium alginate, carboxymethylcellulose, sodium carboxymethylcellulose, hydroxypropylcellulose and hydroxypropylmethylcellulose; Polyhydric alcohols such as glycerin, polyethylene glycol (macrogol), polyethylene glycol and 1,3-butanediol; Surfactants such as polyoxyethylene derivatives; fragrances such as l-menthol; preservatives such as p-hydroxybenzoate; Purified water; And other suitable fillers may be added.

In the case of a tape, a pressure-sensitive adhesive such as a styrene-isoprene-styrene block copolymer and an acrylate resin; Adhesive resins such as acrylic saturated hydrocarbon resins, hydrogenated rosin resins and terpene resins; Softeners such as liquid gums and liquid paraffin; Antioxidants such as dibutylhydroxytoluene; Polyhydric alcohols such as polyethylene glycol; Adsorption promoters such as oleic acid; Surfactants such as polyoxyethylene derivatives; And other suitable fillers may be added. In addition, water-absorbing polymers such as sodium polyacrylate and polyvinyl alcohol and a small amount of purified water can be added to the preparation of tapes containing water.

In the case of an aerosol agent, bases such as white petrolatum (Vaseline), yellow petrolatum, lanolin, purified beeswax, cetanol, stearyl alcohol, stearic acid, hydrogenated oil, hydrocarbon gel, polyethylene glycol, liquid paraffin and squalane; Oleic acid, isopropyl myristate, glycerol triisooctanoate, crotamitone, diethyl sebacate, diisopropyl sebacate, isopropyl adipate, hexyl laurate, fatty acid, fatty acid ester, vegetable oil, aliphatic alcohol and alcohol A solvent or a stabilizer such as; Tocopherol derivatives, antioxidants such as L-ascorbic acid, dibutylhydroxytoluene and butylhydroxyanisole; preservatives such as p-hydroxybenzoate; Curling agents such as glycerin, propylene glycol and sodium hyaluronate; Surfactants such as polyoxyethylene derivatives, glycerol fatty acid esters, sucrose fatty acid esters, sorbitan fatty acid esters, propylene glycol fatty acid esters and lecithin, carboxyvinyl polymers such as those used in creams, gels or lotions, xanthan gum, carboxymethyl Thickeners such as cellulose and sodium carboxymethylcellulose, hydroxypropylcellulose and hydroxypropylmethylcellulose; Stabilizers; Buffering agents; Sweetener suspension; Emulsifiers; Condiment; antiseptic; Adsorption promoters and other suitable fillers may be added.

For external powders, potato starch, rice starch, corn starch, fillers such as talc and zinc oxide, and other suitable additives may be added.

The external preparation for skin of the present invention may be prepared by mixing well-known ingredients with appropriate bases according to a well-known method for preparing external preparations, and the thus-prepared preparation is applied to lesions as required.

In another aspect of the present invention, there is provided a cosmetic composition for improving or alleviating contact dermatitis comprising as an active ingredient a novel chromonic derivative whitening compound having a structure similar to aloesin, or a pharmaceutically acceptable salt thereof .

In another embodiment of the present invention, the cosmetic composition is characterized by having whitening functionality.

In another embodiment of the present invention, the pharmaceutical composition is characterized by inhibiting the melanogenesis reaction.

The cosmetic composition of the present invention can be prepared in any formulations conventionally produced in the art and can be used in cosmetic formulations such as external ointments for skin, essence, whitening cream, lotion, emulsion, pack, general lotion, Serum, cosmetic soap, softening lotion, medicated lotion, hair tonic, whole body cleanser, oil gel and the like.

When the formulation of the present invention is a paste, a cream or a gel, an animal oil, vegetable oil, wax, paraffin, starch, tragacanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide .

When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In the case of a spray, in particular, / Propane or dimethyl ether.

When the formulation of the present invention is a solution or an emulsion, a solvent, a dissolving agent or an emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, , 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan fatty acid esters.

When the formulation of the present invention is a chromone derivative whitening novel compound having a structure similar to aloesin, a liquid diluent such as water, ethanol or propylene glycol, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, and polyoxy A suspending agent such as ethylene sorbitan ester, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.

When the formulation of the present invention is an interfacial active agent-containing cleansing, the carrier component may include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives, or ethoxylated glycerol fatty acid esters.

Hereinafter, the present invention will be described in more detail with reference to Examples and Experimental Examples. It should be understood, however, that the following Examples and Experimental Examples are provided only to facilitate understanding of the present invention and are not intended to limit the scope of the present invention thereto.

Example 1. Preparation of Chromone Derivatives

Compounds of formula 3 were prepared according to scheme 1 below.

[Reaction Scheme 1]

The compound of formula (1) or (2) may be prepared by introducing an appropriate substituent into the compound of formula (3).

Experimental Example 1: Measurement of in vitro tyrosinase inhibitory activity (Tyrosinase inhibition assay)

A tyrosinase inhibitory activity measuring method was carried out. 20 μl of each sample was added to 220 μl of a 0.1 M phosphate buffer (pH 6.5) in a 96-well plate, and then 20 μl of mushroom tyrosinase (1500 U / ml) was added thereto, and 1.5 mM 40 μl of L-tyrosine was added and reacted at 37 ° C for 15 minutes. DOPA chrome produced in the reaction solution was measured with an ELISA (BioTek, USA) at a wavelength of 595 nm.

Experimental Example 2:

The B16F10 cell line, a human melanoma melanoma cell line, was purchased from the Korean Cell Line Bank (KCLB, Korea) and used for the experiment.

Experimental Example 3: Cell culture

B16F10, a malignant melanoma cell line, was cultured in Dulbecco's Modified Eagle's Medium medium supplemented with 10% fetal bovine serum (FBS) (Gibco LOT.No. 1006842, FBS) and penicillin-streptomycin (100 units / Lonza Walkersville, Inc., Walkersville, MD, USA). During the experiment cells were cultured in 5% CO ₂ environment at 37 ℃.

EXPERIMENTAL EXAMPLE 4: Protein expression assay (Western blot analysis)

B16-F10 melanoma cells (melanoma cell) for 10% FBS, penicillin-temperature streptomycin (penicillin-streptomycin) dispensed in 100 mm ² dishes at a density of 1 × 10 ⁵ cells in DMEM supplemented with 1% to 37 ℃ and CO ₂ And cultured in a 5% thermostat.

The culture medium was removed, and the sample was diluted in the medium for each concentration, and then the final 200 nM α-MSH was added thereto, followed by further incubation for 48 hours. The cultured cells were washed with PBS, transferred to a 1.5-mL microtube, and the cells were disrupted by adding a pro-prep protein extraction solution to the cells, followed by centrifugation at 15,000 rpm for 20 minutes at 4 ° C The supernatant was removed to isolate the protein. The separated proteins were quantified according to the BCA method, electrophoresed using a 12% SDS-polyacrylamide gel, and then the PVDF membrane was activated with MeOH. Transferred to a PVDF membrane (Bio-Rad, Hercules, CA, USA). The membrane was blocked in blocking buffer (Tris-buffered saline containing 5% skim milk and Tween 20) for 1 h to block nonspecific binding of the antibody. After that, overnight reaction was performed in a cold chamber at 4 ° C with a primer antibody as an antibody against each of the test proteins. The membrane was then washed three times for 2 minutes with a Tris-buffered saline (TBS-T) containing 0.1% Tween 20 and incubated with secondary antibody conjugated with horseradish peroxidase Secondary antibodies were reacted at room temperature for 1 hour, then washed again and treated with ECL (enhanced chemiluminescence) detection kit (Ge-Healthcare, Buckinghamshire, UK). Protein expression was then confirmed by ImageQuant LAS4000 (Ge-Healthcare, Buckinghamshire, UK). The intensity of the developed band was confirmed. β-actin was used as a control to determine whether each sample contained an oriental protein.

Claims (11)

A cosmetic composition for whitening comprising a chromone derivative having a chemical structure represented by the following formula (1) or (2) or a salt thereof:
[Chemical Formula 1]

(2)

Wherein each of R ₁ and R ₂ is independently a hydrogen atom, a halogen atom, an alkoxy group, an OH group, an alkyl group, a cycloalkyl, an aryl or a monovalent group.
The method according to claim 1,
R ₁ is a hydrogen atom, a halogen atom, C _{1 - 4} alkoxy groups, OH groups, C _{1 - 6} alkyl, cycloalkyl, characterized in that the aryl or be put ventilation, whitening cosmetic composition.
The method according to claim 1,
R ₂ is a hydrogen atom, a halogen atom, a C _1-4 alkoxy group, an OH group, a C _1-6 alkyl group, a cycloalkyl, an aryl or a monovalent group.
The method according to claim 1,
Wherein the chromone derivative inhibits the activity of tyrosinase.
The method according to claim 1,
Wherein the content of the chromone derivative is 0.000001 to 5.0% by weight based on the total weight of the composition.
The method according to claim 1,
The composition may be selected from the group consisting of lotion, nutritional cream, nutritional lotion, eye cream, essence, cleansing cream, cleansing lotion, pack, body lotion, body cream, body essence, makeup base, foundation, ointment, gel, Wherein the composition is formulated in the form of one type of cosmetic composition for skin whitening.
The method according to claim 1,
A whitening dermatological external preparation composition comprising a chromone derivative having a chemical structure represented by the following formula (1) or (2) or a salt thereof:
[Chemical Formula 1]

(2)

Wherein each of R ₁ and R ₂ is independently a hydrogen atom, a halogen atom, an alkoxy group, an OH group, an alkyl group, a cycloalkyl, an aryl or a monovalent group.
8. The method of claim 7,
R ₁ is a hydrogen atom, a halogen atom, C _{1 - 4} alkoxy groups, OH groups, C _{1 - 6} alkyl, cycloalkyl, aryl, or be put characterized in that the ventilation, the external preparation for skin whitening composition.
8. The method of claim 7,
R ₂ is a hydrogen atom, a halogen atom, C _{1 - 4} alkoxy groups, OH groups, C _{1 - 6} alkyl, cycloalkyl, aryl, or be put characterized in that the ventilation, the external preparation for skin whitening composition.
8. The method of claim 7,
Wherein the chromone derivative inhibits the activity of tyrosinase.
8. The method of claim 7,
Wherein the content of the chromone derivative is 0.001 to 10.0% by weight based on the total weight of the composition.

Images